Also categorized in News:
4,000-Year-Old Jar of Headless Toads Discovered in Jerusalem Burial
x hide permanently

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

PR Newswire

"We appreciate and continue to benefit from BARDA's ongoing support in the development of Reltecimod as a novel, host-based, immunomodulatory therapy to treat severe infections," said Dan Teleman, Chief Executive Officer of Atox Bio. "We have a very collaborative partnership with BARDA and look forward to continuing to work together." Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe infections. By limiting, but not inhibiting, the body's acute inflammatory response, Reltecimod helps control the cytokine storm that could quickly lead to morbidity and mortality ...

Mentions: Yissum